Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract Tumors

​ Conditions: Biliary Tract Cancer

Interventions: Drug: Zanidatamab

Sponsors: Anhui Provincial Hospital

Not yet recruiting Conditions: Biliary Tract Cancer
Interventions: Drug: Zanidatamab
Sponsors: Anhui Provincial Hospital
Not yet recruiting